<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Infectious Diseases in Pregnancy - National Guidelines</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
        MathJax = {
            tex: {
                inlineMath: [['$', '$'], ['\\(', '\\)']],
                displayMath: [['$$', '$$'], ['\\[', '\\]']],
                processEscapes: true,
                processEnvironments: true,
                tags: 'ams'
            },
            svg: { fontCache: 'global' },
            options: {
                skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
            }
        };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>

<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon">üè†</span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="07-medical-disorders-diabetes.html" class="nav-button">
                        <span class="nav-icon">‚Üê</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                        <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 44%;"></div>
                        </div>
                        <span class="progress-text">Section 8 of 18</span>
                    </div>
                    <a href="09-mental-health-and-normal-labour.html" class="nav-button">
                        <span class="nav-text">Next: Mental Health & Normal Labour</span>
                        <span class="nav-icon">‚Üí</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">INFECTIOUS DISEASES IN PREGNANCY</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">

                <!-- START: syphilis-pregnancy -->
                <section id="syphilis-pregnancy" class="content-section">
                    <h2 class="section-heading">SYPHILIS IN PREGNANCY</h2>
                    <div class="content-card">
                        <h3>Introduction</h3>
                        <p>Sexually transmitted infections (STIs) are a major public health problem worldwide with
                            direct and indirect impacts affecting quality of life and causing serious morbidity and
                            mortality. STIs have a direct impact on reproductive and child health through infertility,
                            cancers and pregnancy complications and an indirect impact through their role in
                            facilitating sexual transmission of human immunodeficiency virus (HIV) and on national and
                            individual economies through increased morbidity and mortality.</p>
                        <p>Simple, cost-effective screening and treatment options during pregnancy can eliminate most of
                            these complications. Screening all pregnant women for syphilis at first antenatal care visit
                            is recommended in many countries of the world and is being scaled up rapidly in countries
                            committed to the elimination of mother-to-child transmission (EMTCT) of HIV and syphilis.
                        </p>

                        <h3>Epidemiology</h3>
                        <p>In 2015, nearly 1 million pregnant women worldwide were infected with Syphilis. In 2012, an
                            estimated 350,000 adverse pregnancy outcomes worldwide were attributed to syphilis,
                            including 143,000 early foetal deaths/stillbirths, 62,000 neonatal deaths, 44,000
                            preterm/low-birth-weight babies and 102,000 infected infants.</p>

                        <figure>
                            <img src="../../../../../assets/images/2025_11_24_1f5d3abc0b734f89226ag-186-1.jpg"
                                alt="Figure 30: The end-term targets for eMTCT of HIV and syphilis"
                                class="content-image">
                            <figcaption>Figure 30: The end-term targets for eMTCT of HIV and syphilis</figcaption>
                        </figure>

                        <h3>Recommendations</h3>
                        <ul class="enhanced-list">
                            <li>All women should be screened serologically for syphilis early in pregnancy</li>
                            <li>For communities and populations in which the prevalence of syphilis is high and for
                                women at high risk for infection, serologic testing should also be performed twice
                                during the third trimester: once at 28-32 weeks' gestation and again at delivery.</li>
                            <li>Any woman who has a foetal death after 20 weeks' gestation should be tested for
                                syphilis.</li>
                            <li>No mother or neonate should leave the hospital without maternal serologic status having
                                been documented at least once during pregnancy, and if the mother is considered high
                                risk, documented at delivery</li>
                        </ul>

                        <h3>Clinical features based on the stage of disease</h3>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 32: The clinical features of Syphilis</caption>
                                <thead>
                                    <tr>
                                        <th>Stage</th>
                                        <th>Presentation</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Primary</td>
                                        <td>Lesions begin as a raised papule that ulcerates (chancre) and may:
                                            <ul>
                                                <li>Be painless or painful (approximately half reported as painful)</li>
                                                <li>Be solitary or multiple (approximately one third reported as
                                                    multiple)</li>
                                                <li>Typically occur at the site of inoculation (e.g. vagina, penis,
                                                    anus, rectum, lips, in or on the mouth)</li>
                                                <li>Discharge clear serum-may also be purulent, destructive</li>
                                                <li>Spontaneously heals within three to six weeks without treatment</li>
                                            </ul>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>Secondary</td>
                                        <td>
                                            <ul>
                                                <li>Follows untreated primary stage four to eight weeks after appearance
                                                    of the primary lesion (can occur while primary lesion still present)
                                                </li>
                                                <li>Diffuse inflammatory response characterised by generalised
                                                    mucocutaneous lesions affecting skin, mucous membranes and lymph
                                                    nodes</li>
                                                <li>Rash may be generalised but characteristically affects palms and
                                                    soles</li>
                                                <li>Often symmetrical and non-itchy</li>
                                                <li>In warm and moist areas of the body (e.g. anus, labia) flat,
                                                    wart-like plaques develop (condylomata lata)</li>
                                                <li>Resolves spontaneously without treatment in 3-12 weeks</li>
                                            </ul>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>Latent</td>
                                        <td>
                                            <ul>
                                                <li>May be divided into:
                                                    <ul>
                                                        <li>Early latent (infection for less than two years)</li>
                                                        <li>Late latent (infection for two years or more)</li>
                                                        <li>Syphilis of unknown duration</li>
                                                    </ul>
                                                </li>
                                                <li>Characterised by reactive serology with no clinical manifestations
                                                </li>
                                                <li>If untreated 15-40% develop tertiary infection</li>
                                            </ul>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td>Tertiary</td>
                                        <td>
                                            <ul>
                                                <li>Can affect any organ system</li>
                                                <li>Occurs in approximately one-third of untreated patients</li>
                                                <li>Main manifestations are:
                                                    <ul>
                                                        <li>Neurological disease (neurosyphilis)</li>
                                                        <li>Cardiovascular disease (cardiosyphilis)</li>
                                                        <li>Gummatous lesions (gumma)</li>
                                                    </ul>
                                                </li>
                                            </ul>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>Screening strategies</h3>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 33: WHO recommendations for maternal syphilis screening</caption>
                                <thead>
                                    <tr>
                                        <th>Recommendations</th>
                                        <th>Strength of recommendation</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>The WHO STI guideline recommends screening all pregnant women for syphilis
                                            during the first antenatal care visit.</td>
                                        <td>Strong recommendation, moderate-quality evidence</td>
                                    </tr>
                                    <tr>
                                        <td>In settings with low coverage of syphilis screening and treatment for
                                            pregnant women, high loss to follow-up of pregnant women, or limited
                                            laboratory capacity, the WHO STI guideline suggests on-site tests
                                            (Strategies A, B and C) rather than the standard off-site laboratory-based
                                            screening and treatment strategy.</td>
                                        <td>Conditional recommendation, low-quality evidence</td>
                                    </tr>
                                    <tr>
                                        <td>In settings with a low prevalence of syphilis (below 5%), the WHO STI
                                            guideline suggests a single on-site rapid syphilis test (RST) be used to
                                            screen pregnant women (Strategy A) rather than a single on-site rapid plasma
                                            reagin (RPR) test (Strategy B).</td>
                                        <td>Conditional recommendation, low-quality evidence</td>
                                    </tr>
                                    <tr>
                                        <td>In settings with a high prevalence of syphilis (5% or greater), the WHO STI
                                            guideline suggests an on-site rapid syphilis test (RST) and, if positive,
                                            provision of a first dose of treatment and a rapid plasma reagin (RPR) test,
                                            and then, if the RPR test is positive, provision of treatment according to
                                            duration of syphilis (Strategy C).</td>
                                        <td>Conditional recommendation, low-quality evidence</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>Effect of Syphilis on Pregnancy</h3>
                        <p>Syphilis in primary, secondary and latent phase if untreated is associated with severe
                            adverse pregnancy outcomes. It is advisable to treat before the second trimester.</p>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 34: The effects of syphilis on pregnancy</caption>
                                <tbody>
                                    <tr>
                                        <td><strong>Maternal impact</strong></td>
                                        <td>
                                            <ul>
                                                <li>Maternal syphilis is thought to increase the risk of vertical
                                                    transmission of HIV and other sexually transmitted infections (STI)
                                                </li>
                                                <li>Approximately 50% of women with syphilis requiring treatment in
                                                    pregnancy suffer adverse pregnancy outcomes</li>
                                                <li>In the absence of effective treatment maternal/foetal impacts
                                                    include: 25% second trimester miscarriage/stillbirth, 11% neonatal
                                                    death at term, 13% preterm or low birth weight infant</li>
                                            </ul>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td><strong>Foetus/baby</strong></td>
                                        <td>
                                            <ul>
                                                <li>Placental infiltration reduces blood flow to the foetus and may lead
                                                    to growth restriction</li>
                                                <li>Rates of transmission to babies born to women with untreated
                                                    syphilis are estimated to be: 70% for primary/secondary, 40% for
                                                    early latent, 10% for late latent</li>
                                            </ul>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td><strong>Longer term implications</strong></td>
                                        <td>
                                            <ul>
                                                <li>27% of untreated babies who survive to 30 days are likely to develop
                                                    symptoms of congenital syphilis (Neurological/developmental delays,
                                                    Musculoskeletal problems)</li>
                                            </ul>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>Treatment</h3>
                        <p>Aims of Syphilitic treatment include: Counselling, Contact tracing, Compliance to treatment,
                            Prevention of in-utero transplacental transfer of the spirochetes, Monitoring of response to
                            treatment.</p>

                        <h4>Early syphilis (primary, secondary and early latent)</h4>
                        <ul class="enhanced-list">
                            <li><strong>Recommended:</strong> Benzathine penicillin G 2.4 million units once
                                intramuscularly.</li>
                            <li><strong>Alternative:</strong> Procaine penicillin 1.2 million units intramuscularly once
                                daily for 10 days.</li>
                            <li><strong>If allergic/not available:</strong> Erythromycin 500 mg orally four times daily
                                for 14 days OR Ceftriaxone 1 g intramuscularly once daily for 10-14 days OR Azithromycin
                                2 g once orally. (Note: Erythromycin/Azithromycin do not cross placental barrier
                                completely; fetus is not treated).</li>
                        </ul>

                        <h4>Late syphilis (infection > 2 years or unknown duration)</h4>
                        <ul class="enhanced-list">
                            <li><strong>Recommended:</strong> Benzathine penicillin G 2.4 million units intramuscularly
                                once weekly for three consecutive weeks.</li>
                            <li><strong>Alternative:</strong> Procaine penicillin 1.2 million units intramuscularly once
                                a day for 20 days.</li>
                            <li><strong>If allergic/not available:</strong> Erythromycin 500 mg orally four times daily
                                for 30 days.</li>
                        </ul>

                        <aside class="callout warning" role="alert">
                            <h4 class="callout-title"><span class="callout-icon">‚ö†Ô∏è</span> Important Notes</h4>
                            <ul>
                                <li>Doxycycline should not be used in pregnant women.</li>
                                <li>Women treated for syphilis during the second trimester are at risk for premature
                                    labour and/or non-reassuring foetal status if the treatment precipitates the
                                    Jarisch-Herxheimer reaction.</li>
                                <li>Missed doses are not acceptable for pregnant women receiving therapy for late latent
                                    syphilis. Pregnant women who miss any dose of therapy must repeat the full course of
                                    therapy.</li>
                                <li>All women who have syphilis should be offered testing for HIV infection.</li>
                            </ul>
                        </aside>

                        <figure>
                            <img src="../../../../../assets/images/2025_11_24_1f5d3abc0b734f89226ag-195-2.jpg"
                                alt="Figure 31: Algorithm for the Management of Genital Ulcer Syndrome"
                                class="content-image">
                            <figcaption>Figure 31: Algorithm for the Management of Genital Ulcer Syndrome</figcaption>
                        </figure>
                    </div>
                </section>
                <!-- END: syphilis-pregnancy -->

                <!-- START: malaria-pregnancy -->
                <section id="malaria-pregnancy" class="content-section">
                    <h2 class="section-heading">MALARIA IN PREGNANCY</h2>
                    <div class="content-card">
                        <h3>Introduction</h3>
                        <p>Malaria is a protozoan infection by the Plasmodium species. The plasmodium parasite is
                            transmitted by the female Anopheles mosquito. Annually, around 125 million pregnancies
                            around the world are at risk from malaria. In sub-Saharan Africa, an estimated 25 million
                            pregnant women are at risk of infection yearly.</p>
                        <p>Malaria in pregnancy is a significant contributing factor to maternal death. It was estimated
                            to have been responsible for approximately 15% of maternal deaths globally. Annually,
                            Malaria in pregnancy is responsible for 20% of stillbirths and 11% of neonatal deaths in
                            sub-Saharan Africa.</p>

                        <figure>
                            <img src="../../../../../assets/images/2025_11_24_1f5d3abc0b734f89226ag-198-1.jpg"
                                alt="Figure 32: Global Malaria Distribution" class="content-image">
                            <figcaption>Figure 32: Global Malaria Distribution</figcaption>
                        </figure>

                        <figure>
                            <img src="../../../../../assets/images/2025_11_24_1f5d3abc0b734f89226ag-199-1.jpg"
                                alt="Figure 33: Kenyan map showing Malaria endemicity zones" class="content-image">
                            <figcaption>Figure 33: Kenyan map showing Malaria endemicity zones</figcaption>
                        </figure>

                        <h3>Pathophysiology</h3>
                        <p>Increased susceptibility to malaria infection during pregnancy results in high parasitemia
                            and heavy infiltration of parasite-infected RBCs in placental vasculature, a privilege site
                            where the parasite can evade maternal immune response especially filtration by the spleen.
                        </p>
                        <figure>
                            <img src="../../../../../assets/images/2025_11_24_1f5d3abc0b734f89226ag-200-1.jpg"
                                alt="Figure 34: Life cycle of the malaria parasite" class="content-image">
                            <figcaption>Figure 34: Life cycle of the malaria parasite</figcaption>
                        </figure>

                        <h3>Prevention</h3>
                        <p>WHO recommends the following package of interventions for the prevention and treatment of
                            malaria during pregnancy:</p>
                        <ul class="enhanced-list">
                            <li>Use of long-lasting insecticidal nets (LLINs)</li>
                            <li>In all areas with moderate to high malaria transmission in Africa, intermittent
                                preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP), as part of
                                antenatal care services</li>
                            <li>Prompt diagnosis and effective treatment of malaria infections.</li>
                            <li>Indoor residual spraying in malaria-endemic zones</li>
                            <li>Use of malaria vaccine</li>
                        </ul>

                        <div class="table-container">
                            <table class="content-table">
                                <caption>Figure 36: showing ANC contact schedule with proposed MiP intervention
                                    timelines</caption>
                                <thead>
                                    <tr>
                                        <th>ANC Contact</th>
                                        <th>IPTp-SP Dose</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Contact 1: Up to 12 weeks</td>
                                        <td>Counsel to return at 13-16 weeks</td>
                                    </tr>
                                    <tr>
                                        <td>Additional contact (1a): 13-16 weeks</td>
                                        <td>IPTp-SP dose 1</td>
                                    </tr>
                                    <tr>
                                        <td>Contact 2: 20 weeks</td>
                                        <td>IPTp-SP dose 2</td>
                                    </tr>
                                    <tr>
                                        <td>Contact 3: 26 weeks</td>
                                        <td>IPTp-SP dose 3</td>
                                    </tr>
                                    <tr>
                                        <td>Contact 4: 30 weeks</td>
                                        <td>IPTp-SP dose 4</td>
                                    </tr>
                                    <tr>
                                        <td>Contact 5: 34 weeks</td>
                                        <td>IPTp-SP dose 5</td>
                                    </tr>
                                    <tr>
                                        <td>Contact 6: 36 weeks</td>
                                        <td>No SP administration</td>
                                    </tr>
                                    <tr>
                                        <td>Contact 7: 38 weeks</td>
                                        <td>IPTp-SP dose 6 (if missed earlier)</td>
                                    </tr>
                                    <tr>
                                        <td>Contact 8: 40 weeks</td>
                                        <td></td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                        <aside class="callout note" role="note">
                            <h4 class="callout-title"><span class="callout-icon">‚ÑπÔ∏è</span> Note</h4>
                            <p>Pregnant women on co-trimoxazole should not receive IPTp-SP due to an increased risk of
                                adverse events when both drugs are given in parallel.</p>
                        </aside>

                        <h3>Clinical features</h3>
                        <h4>Uncomplicated malaria</h4>
                        <p>Symptoms include: Fever, Chills, Muscle and joint aches, Anorexia, Vomiting, Headache,
                            Lethargy, Abdominal discomfort and diarrhea.</p>

                        <h4>Severe Malaria</h4>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Figure 37: Signs and symptoms of Malaria</caption>
                                <thead>
                                    <tr>
                                        <th>UNCOMPLICATED MALARIA</th>
                                        <th>SEVERE MALARIA</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>
                                            One or more of the following clinical features in the presence of malaria
                                            parasitemia or positive RDT:<br>
                                            Axillary temperature $\le 37.5^{\circ}C$ and/or history of recent fever/and
                                            or presence of anemia
                                        </td>
                                        <td>
                                            <strong>Clinical Features:</strong>
                                            <ul>
                                                <li>Impaired consciousness/coma</li>
                                                <li>Prostration/generalized weakness</li>
                                                <li>Multiple convulsions (>2 within 24hours)</li>
                                                <li>Deep breathing/respiratory distress</li>
                                                <li>Acute Pulmonary edema</li>
                                                <li>Circulatory collapse/shock (systolic BP &lt; 80 mm/Hg)</li>
                                                <li>Acute Kidney Injury</li>
                                                <li>Clinical Jaundice</li>
                                                <li>Significant bleeding</li>
                                            </ul>
                                            <strong>Laboratory Findings:</strong>
                                            <ul>
                                                <li>Hypoglycaemia (blood glucose &lt; 2.2 mmol/l)</li>
                                                <li>Metabolic acidosis</li>
                                                <li>Severe normocytic anemia (Hb &lt; 7g/dl)</li>
                                                <li>Hemoglobinuria</li>
                                                <li>Hyperparasitemia</li>
                                                <li>Renal impairment</li>
                                            </ul>
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>Treatment of malaria in pregnancy</h3>
                        <h4>Uncomplicated malaria</h4>
                        <ul class="enhanced-list">
                            <li><strong>First trimester:</strong> Oral quinine hydrochloride (600 mg every 8 hours) with
                                clindamycin (10 mg/kg twice a day) for 7 days.</li>
                            <li><strong>Second and third trimester:</strong> Artemether-lumefantrine (AL) - 6-dose
                                regimen given over three days (4 tablets stat, repeat after 8 hours, 24hrs, 36hrs, 48hrs
                                and 60 hrs).</li>
                        </ul>

                        <h4>Severe malaria in pregnancy</h4>
                        <p>Intensive care and prompt parenteral antimalarial treatment are crucial.</p>
                        <ul class="enhanced-list">
                            <li><strong>Artesunate:</strong> First choice in all trimesters. Dosage IV 2.4 mg/kg/dose
                                given STAT, at 12 h and at 24 h. Treat for at least 24 h. Once patient can tolerate oral
                                therapy, complete treatment with 3 days of an ACT.</li>
                            <li><strong>Quinine:</strong> Loading dose (20 mg salt/kg) then maintenance dose (10
                                mg/salt) administered at 8 h intervals.</li>
                        </ul>
                        <aside class="callout warning" role="alert">
                            <h4 class="callout-title"><span class="callout-icon">‚ö†Ô∏è</span> Warning</h4>
                            <p>Parenteral quinine has an increased risk of hypoglycemia hence the need for frequent
                                blood glucose monitoring.</p>
                        </aside>

                        <figure>
                            <img src="../../../../../assets/images/2025_11_24_1f5d3abc0b734f89226ag-211-1.jpg"
                                alt="Figure 39: Management of Malaria in Pregnancy" class="content-image">
                            <figcaption>Figure 39: Management of Malaria in Pregnancy</figcaption>
                        </figure>
                    </div>
                </section>
                <!-- END: malaria-pregnancy -->

                <!-- START: hiv-pregnancy -->
                <section id="hiv-pregnancy" class="content-section">
                    <h2 class="section-heading">HIV IN PREGNANCY</h2>
                    <div class="content-card">
                        <h3>Introduction</h3>
                        <p>A key goal of managing HIV in pregnancy and postpartum is to optimize a woman's own health
                            and zero rate infection to the neonate. The transmission of HIV from a HIV-positive mother
                            to her child during pregnancy, labour, delivery or breastfeeding is called mother-to-child
                            transmission. In the absence of any intervention, transmission rates range from 15% to 45%.
                            This rate can be reduced to below 5% with effective interventions.</p>

                        <figure>
                            <img src="../../../../../assets/images/2025_11_24_1f5d3abc0b734f89226ag-216-1.jpg"
                                alt="Figure 40: The Four Prongs to Eliminate MTCT of HIV" class="content-image">
                            <figcaption>Figure 40: The Four Prongs to Eliminate MTCT of HIV</figcaption>
                        </figure>

                        <h3>During Pregnancy and Breastfeeding</h3>
                        <p>Prevention of mother-to-child transmission of HIV (PMTCT) should be offered as part of a
                            comprehensive package of fully integrated, routine antenatal care interventions. Lifelong
                            ART should be initiated in all pregnant and breastfeeding women living with HIV, regardless
                            of gestational age, WHO clinical stage and at any CD4 count.</p>
                        <ul class="enhanced-list">
                            <li>ART should be started, ideally, on the same day as HIV diagnosis is made with ongoing
                                enhanced adherence support</li>
                            <li>The preferred first line ART regimen for pregnant and breastfeeding women is <strong>TDF
                                    + 3TC + DTG</strong> (WHO JULY 2019)</li>
                            <li>For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after
                                initiation, and then every 6 months until complete cessation of breastfeeding</li>
                            <li>All HEI should receive infant ARV prophylaxis consisting of 6 weeks of AZT + NVP and
                                thereafter NVP should be continued until 6 weeks after complete cessation of
                                breastfeeding</li>
                            <li>All infants irrespective of HIV status should be exclusively breastfed for the first 6
                                months of life.</li>
                        </ul>

                        <h3>Intrapartum Management</h3>
                        <ul class="enhanced-list">
                            <li>Minimize vaginal examinations.</li>
                            <li>Avoid routine artificial rupture of membranes (ARM).</li>
                            <li>Avoid routine episiotomy.</li>
                            <li>Minimize the risk of postpartum haemorrhage.</li>
                            <li><strong>Mode of delivery:</strong> Vaginal delivery is appropriate for HIV-infected
                                pregnant women who have been maintained on combined antiretroviral therapy and who have
                                viral loads of 1,000 copies/mL or less at or near delivery. The risk of mother-to-child
                                transmission in HIV-infected women with high viral loads can be reduced by performing
                                caesarean deliveries before the onset of labor and before rupture of membranes.</li>
                        </ul>

                        <h3>Contraception</h3>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Contraceptive Method / ARV Interactions</caption>
                                <thead>
                                    <tr>
                                        <th rowspan="2">Contraceptive Method</th>
                                        <th colspan="4">ARVs Being Used</th>
                                    </tr>
                                    <tr>
                                        <th>NRTI (any)</th>
                                        <th>NNRTI (EFV/NVP)</th>
                                        <th>PI/r (any)</th>
                                        <th>INSTI (DTG)</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>IM medroxyprogesterone (DMPA)</td>
                                        <td>1</td>
                                        <td>1</td>
                                        <td>1</td>
                                        <td>-</td>
                                    </tr>
                                    <tr>
                                        <td>Implants</td>
                                        <td>1</td>
                                        <td>2</td>
                                        <td>2</td>
                                        <td>-</td>
                                    </tr>
                                    <tr>
                                        <td>Combined oral contraceptive (pill)</td>
                                        <td>1</td>
                                        <td>2</td>
                                        <td>2</td>
                                        <td>-</td>
                                    </tr>
                                    <tr>
                                        <td>Intrauterine device (IUD)</td>
                                        <td colspan="4">Category 2 for asymptomatic or mild HIV disease. Category 3 for
                                            women with advanced and symptomatic HIV disease UNTIL they are stable on
                                            ART.</td>
                                    </tr>
                                    <tr>
                                        <td>Condoms</td>
                                        <td colspan="4">No restrictions; use encouraged in combination (dual protection)
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                        <p><em>Category 1: No restriction. Category 2: Advantages generally outweigh risks. Category 3:
                                Risks usually outweigh advantages.</em></p>
                    </div>
                </section>
                <!-- END: hiv-pregnancy -->

                <!-- START: tb-pregnancy -->
                <section id="tb-pregnancy" class="content-section">
                    <h2 class="section-heading">TUBERCULOSIS IN PREGNANCY</h2>
                    <div class="content-card">
                        <h3>Introduction</h3>
                        <p>Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. It is
                            transmitted through aerosolized droplet nuclei. Tuberculosis remains the most common cause
                            of death from infectious agents in childbearing-age women worldwide.</p>

                        <h3>Diagnosis of TB</h3>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 35: Indications for various diagnostic tests</caption>
                                <thead>
                                    <tr>
                                        <th>Laboratory test</th>
                                        <th>Target</th>
                                        <th>Purpose</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>GeneXpert</td>
                                        <td>The first line test for all presumptive TB in: Children, PLHIV, HCWs,
                                            Prisoners, Smear negative persons, Previously treatment TB</td>
                                        <td>For diagnosis of TB Resistance to Rifampicin</td>
                                    </tr>
                                    <tr>
                                        <td>Smear microscopy</td>
                                        <td>All presumptive Pulmonary TB</td>
                                        <td>Detect TB disease. Monitoring smear positive and gene xpert positive TB
                                            patients on treatment at months 2, 5 and 6</td>
                                    </tr>
                                    <tr>
                                        <td>Chest X-ray</td>
                                        <td>All presumptive pulmonary TB</td>
                                        <td>Support TB diagnosis especially where sputum for AFB/gene xpert is negative.
                                        </td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>Treatment of TB in pregnancy</h3>
                        <p>Pregnancy should be avoided during anti-TB treatment. However, when it occurs, termination of
                            pregnancy is not recommended. All pregnant women with active TB should be treated with a
                            full complement of anti-TB drugs.</p>
                        <ul class="enhanced-list">
                            <li><strong>New cases:</strong>
                                <ul>
                                    <li>Intensive phase: 2 months Rifampicin (R), Isoniazid (H), Pyrazinamide (Z),
                                        Ethambutol (E) - (2RHZE)</li>
                                    <li>Continuation phase: 4 months Rifampicin (R) and Isoniazid (H) - (4RH)</li>
                                </ul>
                            </li>
                            <li>Pyridoxine should be given together with isoniazid to avoid neurological congenital
                                malformations in the fetus.</li>
                            <li>Streptomycin is ototoxic and should not be used in pregnancy as it may cause deafness in
                                the infant.</li>
                        </ul>

                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 38: Dosages of drugs used in treatment of TB</caption>
                                <thead>
                                    <tr>
                                        <th>Drug</th>
                                        <th>Formulation</th>
                                        <th>Over 55 kg</th>
                                        <th>40-54 kg</th>
                                        <th>30-39 kg</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>4-FDC tablet RHZE</td>
                                        <td>Tablet</td>
                                        <td>4</td>
                                        <td>3</td>
                                        <td>2</td>
                                    </tr>
                                    <tr>
                                        <td>2-FDC tablet RH</td>
                                        <td>Tablet</td>
                                        <td>4</td>
                                        <td>3</td>
                                        <td>2</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>MDR and XDR TB in Pregnancy</h3>
                        <p>Multi- disciplinary approach with inclusion of a TB specialist and medication and best
                            conducted under directly observed therapy. In pregnancy gestation &lt; 12 weeks Kanamycin
                            and Ethionamide are replaced by PAS.</p>
                    </div>
                </section>
                <!-- END: tb-pregnancy -->

            </main>

            <!-- Bottom Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon">üè†</span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="07-medical-disorders-diabetes.html" class="nav-button">
                        <span class="nav-icon">‚Üê</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                        <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 44%;"></div>
                        </div>
                        <span class="progress-text">Section 8 of 18</span>
                    </div>
                    <a href="09-mental-health-and-normal-labour.html" class="nav-button">
                        <span class="nav-text">Next: Mental Health & Normal Labour</span>
                        <span class="nav-icon">‚Üí</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>

</html>